News & Updates
Filter by Specialty:
Allopurinol use, dose escalation do not increase mortality in gout patients with CKD
In patients with gout and concurrent chronic kidney disease (CKD), the risk of mortality does not seem to increase with initiation of allopurinol, achieving target serum urate (SU) level with allopurinol, or treatment dose escalation, a study has shown.
Allopurinol use, dose escalation do not increase mortality in gout patients with CKD
01 Mar 2022NOACs better than warfarin in diabetic patients with atrial fibrillation
Treatment with nonvitamin K antagonist oral anticoagulants (NOACs) results in lower risks of diabetes complications and mortality compared with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus (DM), suggest a study.
NOACs better than warfarin in diabetic patients with atrial fibrillation
01 Mar 2022High-dose ipilimumab augments nivolumab benefit for TCC
In the phase II TITAN-TCC* trial presented at ASCO GU 2022, the addition of ipilimumab to nivolumab led to improved responses in patients with pretreated (second/third line) advanced/metastatic or surgically unresectable transitional cell carcinoma (TCC).
High-dose ipilimumab augments nivolumab benefit for TCC
01 Mar 2022KEYNOTE-394 a win for Asians with advanced HCC
Combining pembrolizumab with best supportive care (BSC) improved survival and response when used as second-line therapy in Asians with advanced hepatocellular carcinoma (HCC).
KEYNOTE-394 a win for Asians with advanced HCC
01 Mar 2022Early ivermectin does not prevent progression to severe COVID-19
The early addition of ivermectin to standard of care (SoC)* in high-risk patients with mild-to-moderate COVID-19 did not prevent progression to severe disease compared with SoC alone, according to results of the I-TECH** trial conducted in Malaysia.